Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProteoTech has completed regulatory investigational new drug requirements and has received clearance from the FDA to initiate its Phase I human clinical trial on Exebryl-1, a small molecule drug targeting toxic beta-amyloid protein accumulation for the treatment of Alzheimer's disease.
Subscribe to our email newsletter
Initial studies suggest that Exebryl-1 may have an important dual capacity by inhibiting and reducing tau protein from forming paired helical filaments, important in neurofibrillary tangle formation. The presence of neurofibrillary tangles in brain containing tau protein is said to be an important pathological hallmark of Alzheimer’s disease. Further studies are ongoing to confirm these findings.
According to the company, Exebryl-1 may be the first orally bioavailable small molecule drug that affects both amyloid plaque and neurofibrillary tangle accumulation, the two major characteristic and pathological lesions of Alzheimer’s disease.
Exebryl-1 is a small molecule drug developed at ProteoTech from its library of small molecule compounds designed to target specific amyloid diseases.